ProCE Banner Activity

Managing Adverse Events With Combination Immune Checkpoint Inhibitor/Targeted Therapy


Download these slides from Eric Jonasch, MD, and Kathleen Moore, MD, for multidisciplinary strategies to identify and manage adverse events associated with immune checkpoint inhibitors as single agents and in combination with VEGF-targeted agents or PARP inhibitors.

Released: May 19, 2023



Eric Jonasch

Eric Jonasch, MD

Professor, Department of GU Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Kathleen N. Moore

Kathleen N. Moore, MD, MS

Virginia Kerley Cade Chair in Developmental Therapeutics
Deputy Director
Associate Director Clinical Research
Stephenson Cancer Center at OU Health
Oklahoma City, Oklahoma

Provided by

ProCE Banner


Supported by educational grants from AstraZeneca, Eisai, Merck Sharp & Dohme LLC, and Regeneron Pharmaceuticals, Inc.



Merck Sharp & Dohme, LLC

Regeneron Pharmaceuticals, Inc